Status:
COMPLETED
Treatment of High Altitude Polycythemia by Acetazolamide
Lead Sponsor:
Association pour la Recherche en Physiologie de l'Environnement
Collaborating Sponsors:
University of Paris 13
Universidad Peruana Cayetano Heredia
Conditions:
High Altitude Polycythemia
Eligibility:
MALE
18-65 years
Phase:
PHASE4
Brief Summary
The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and 15% in the high altitude regions of South America. There is no pharmacological treatment available. After a...
Detailed Description
Chronic mountain sickness (CMS) is characterized by an excessive number of red cells in the blood of persons living permanently above the altitude of 2,500m. The symptoms of this very incapacitating d...
Eligibility Criteria
Inclusion
- patients with Chronic mountain sickness and Hb \> 21g/dl
Exclusion
- patients smokers
- patients with respiratory or cardiovascular or renal disease
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2007
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00424970
Start Date
January 1 2007
End Date
November 1 2007
Last Update
January 24 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Cayetano Heredia
Lima, Peru, 100